Vaxcyte (NASDAQ:PCVX) Sets New 1-Year High at $86.14

Vaxcyte, Inc. (NASDAQ:PCVX) reached a new 52-week high during trading on Wednesday . The company traded as high as $86.14 and last traded at $85.49, with a volume of 107459 shares trading hands. The stock had previously closed at $83.95.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Friday, June 28th.

Vaxcyte Trading Up 1.4 %

The stock has a market capitalization of $9.26 billion, a PE ratio of -19.89 and a beta of 0.97. The firm has a 50-day moving average price of $75.25 and a 200-day moving average price of $70.25.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.28. Sell-side analysts expect that Vaxcyte, Inc. will post -3.93 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $74.99, for a total value of $599,920.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares of the company’s stock, valued at approximately $7,174,968.21. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the senior vice president now owns 12,723 shares of the company’s stock, valued at approximately $1,017,840. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $74.99, for a total value of $599,920.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $7,174,968.21. The disclosure for this sale can be found here. Insiders sold a total of 88,766 shares of company stock valued at $6,659,541 in the last ninety days. 3.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Xponance Inc. boosted its stake in Vaxcyte by 3.0% in the 4th quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after purchasing an additional 163 shares during the period. Ellsworth Advisors LLC boosted its stake in Vaxcyte by 2.6% in the 4th quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after purchasing an additional 207 shares during the period. Parallel Advisors LLC boosted its stake in Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vaxcyte by 0.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after purchasing an additional 296 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Vaxcyte by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock worth $1,382,000 after purchasing an additional 376 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.